Inclusion Criteria:  Male or female aged ≥18 years and ≤75 years at the time of signing the ICF; Dose Escalation Period: Histopathologically documented incurable advanced malignancies with standard treatment failure; At least one measurable lesion that meets RECIST 1.1 criteria in case of solid tumors; An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1; Life expectancy ≥3 months; Adequate organ functions as defined; Ability to understand and voluntarily agrees to participate by giving written informed consent for the study.  Exclusion Criteria:  The imaging examinations shows the tumor invades large blood vessels; Or as the assessment of the investigator, the tumor is highly likely to invade important blood vessels which would cause fatal bleeding during treatment; The imaging examinations shows significant pulmonary cavitary tumors occurs with the bleeding risk as the investigator's assessment; patients with active brain metastasis (without medical control or with clinical symptoms), cancerous meningitis, or spinal cord compression; Uncontrollable pleural effusion, pericardial effusion or peritoneal effusion, with clinical symptoms; Severe bong injury caused by metastatic tumor of bone; Prior malignancy (other than current malignant tumor) within 3 years before the first dose of study treatment; History of autoimmune diseases; Evidence or history of arterial/venous thrombosis within 6 months before the first dose; Patients with interstitial pneumonitis or interstitial lung disease; past history of interstitial pneumonitis or interstitial lung disease requiring hormone therapy; When receiving immune checkpoint inhibitors previously, myocarditis related with immune, ≥ grade 2 of pneumonia related with immune or ≥ grade 3 of other adverse reactions related with immune occurred.